These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 19934303)

  • 41. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
    Ghosh R; Narasanna A; Wang SE; Liu S; Chakrabarty A; Balko JM; González-Angulo AM; Mills GB; Penuel E; Winslow J; Sperinde J; Dua R; Pidaparthi S; Mukherjee A; Leitzel K; Kostler WJ; Lipton A; Bates M; Arteaga CL
    Cancer Res; 2011 Mar; 71(5):1871-82. PubMed ID: 21324925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF; Kane SE; Sonenshein GE
    Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling.
    Le XF; Lammayot A; Gold D; Lu Y; Mao W; Chang T; Patel A; Mills GB; Bast RC
    J Biol Chem; 2005 Jan; 280(3):2092-104. PubMed ID: 15504738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
    Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
    Mohd Sharial MSN; Crown J; Hennessy BT
    Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Dockx Y; Vangestel C; De Bruycker S; Van den Wyngaert T; Huizing M; Staelens S; Stroobants S
    Cancer Biother Radiopharm; 2023 Feb; 38(1):51-61. PubMed ID: 36472460
    [No Abstract]   [Full Text] [Related]  

  • 49. RON confers lapatinib resistance in HER2-positive breast cancer cells.
    Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
    Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
    Rimawi MF; Wiechmann LS; Wang YC; Huang C; Migliaccio I; Wu MF; Gutierrez C; Hilsenbeck SG; Arpino G; Massarweh S; Ward R; Soliz R; Osborne CK; Schiff R
    Clin Cancer Res; 2011 Mar; 17(6):1351-61. PubMed ID: 21138857
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of PI3K/Akt/mTOR inhibitors combined with trastuzumab therapy for HER2-positive breast cancer: a meta-analysis.
    Peng DS; Huang BQ; Ning HT; Zhu XZ
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7667-7678. PubMed ID: 36314338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
    Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
    PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HER2+ breast cancer therapy: by CPP-ZFN mediated targeting of mTOR?
    Puria R; Sahi S; Nain V
    Technol Cancer Res Treat; 2012 Apr; 11(2):175-80. PubMed ID: 22335412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
    Serra V; Scaltriti M; Prudkin L; Eichhorn PJ; Ibrahim YH; Chandarlapaty S; Markman B; Rodriguez O; Guzman M; Rodriguez S; Gili M; Russillo M; Parra JL; Singh S; Arribas J; Rosen N; Baselga J
    Oncogene; 2011 Jun; 30(22):2547-57. PubMed ID: 21278786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
    Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
    Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. β2-AR signaling controls trastuzumab resistance-dependent pathway.
    Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
    Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in
    Gambardella V; Gimeno-Valiente F; Tarazona N; Martinez-Ciarpaglini C; Roda D; Fleitas T; Tolosa P; Cejalvo JM; Huerta M; Roselló S; Castillo J; Cervantes A
    Clin Cancer Res; 2019 Mar; 25(5):1639-1649. PubMed ID: 30504425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.